NK-104, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, reduces osteopontin expression by rat aortic smooth muscle cells

British Journal of Pharmacology

Volumn 133, Issue 1, 2001, Pages 83-88

  Takemoto, Minoru ^a   Kitahara, Masaki ^b   Yokote, Koutaro ^a   Asaumi, Sunao ^a   Take, Ayako ^a   Saito, Yasushi ^a   Mori, Seijiro ^a  

^a CHIBA UNIVERSITY   (Japan)

^b NISSAN CHEMICAL INDUSTRIES LTD   (Japan)

Author keywords

3 hydroxy 3 methylglutaryl coenzyme A reductase; Diabetic macroangiopathy; Osteopontin; Statin; Vascular smooth muscle cells

Indexed keywords

ATORVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MESSENGER RNA; MEVALONIC ACID; OSTEOPONTIN; PITAVASTATIN; STREPTOZOCIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; AORTA MEDIA; ARTICLE; ATHEROSCLEROSIS; CHOLESTEROL SYNTHESIS; CONTROLLED STUDY; DIABETIC ANGIOPATHY; DRUG EFFICACY; DRUG INHIBITION; DRUG MECHANISM; HYPERCHOLESTEROLEMIA; MALE; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT;

EID: 0034987274     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0704046     Document Type: Article

References (30)

1. Pharmacological profile of a novel synthetic inhibitor of 3-hydroxy-3- methylglutaryl-coenzyme A reductase
2. The nature and significance of osteopontin
3. p21Ras is modified by a farnesyl isoprenoid
4. New insights into the pharmacodynamic and pharmacokinetic properties of statins
5. Specific labeling of isoprenylated proteins: Application to study inhibitors of the post- translational farnesylation and geranylgeranylation
6. Osteopontin: A protein with diverse functions
7. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS
8. Upregulation of osteopontin expression in renal cortex of streptozotocin-induced diabetic rats is mediated by bradykinin
9. Identification of a ras-activated enhancer in the mouse osteopontin promoter and its interaction with a putative ETS-related transcription factor whose activity correlates with the metastatic potential of the cell
10. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum
11. Management of primary hyperlipidemia
12. Abnormal metabolism of polyunsaturated fatty acid and phospholipids in diabetic glomeruli
13. NK-104, a newly developed HMG-CoA reductase inhibitor, suppresses neointimal thickening by inhibiting smooth muscle cell growth and fibronectin production in ballooninjured rabbit carotid artery
14. Neutralizing antibodies directed against osteopontin inhibit rat carotid neointimal thickening after endothelial denudation
15. Prevention of cardio-vascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels
16. Which drugs benefit diabetic patients for secondary prevention of myocardial infarction?
17. Upstream stimulatory factor 1 regulates osteopontin expression in smooth muscle cells
18. Platelet-derived growth factor is a potent stimulator of expression of intercellular adhesion molecule-1 in human arterial smooth muscle cells
19. Collagen secretion and growth of mesangial cells require geranylgeranylpyrophosphate
20. Identification of a DNA sequence responsible for the binding of the 1,25-dihydroxyvitamin D3 receptor and 1,25-dihydroxyvitamin D3 enhancement of mouse secreted phosphoprotein 1 (SPP-1 or osteopontin) gene expression
21. Antiatherothrombotic properties of statins
22. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels
23. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
24. High expression of genes for calcification-regulating proteins in human atherosclerotic plaques
25. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia
26. Effects of aging and hyperlipidemia on plasma osteopontin level
27. Enhanced expression of osteopontin in human diabetic artery and analysis of its functional role in accelerated atherogenesis
28. Enhanced expression of osteopontin by high glucose in cultured rat aortic smooth muscle cells
29. Stimulation of mouse osteopontin promoter by v-Src is mediated by a CCAAT box-binding factor
30. Diet-induced diabetes activates an osteogenic gene regulatory program in the aortas of low density lipoprotein receptor-deficient mice